Skip to Content

Keveyis Approval History

FDA Approved: Yes (First approved August 7, 2015)
Brand name: Keveyis
Generic name: dichlorphenamide
Dosage form: Tablets
Company: Taro Pharmaceutical Industries Ltd.
Treatment for: Primary Hyperkalemic and Hypokalemic Periodic Paralysis

Keveyis (dichlorphenamide) is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis.

Development History and FDA Approval Process for Keveyis

DateArticle
Aug 10, 2015Approval FDA Approves Keveyis (dichlorphenamide) for Primary Hyperkalemic and Hypokalemic Periodic Paralysis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide